MDMA therapy company Lykos raises $100M in Series A funding as it eyes FDA approval
MAPS Public Benefit Corp. said Friday it raised $100 million in an oversubscribed Series A round of financing as it works to win approval from the U.S. Food and Drug Administration to become the first provider of psychedelic-assisted therapy PTSD.
MAPS Public Benefit Corp. said Friday it raised $100 million in an oversubscribed Series A round of financing as it works to win approval from the U.S. Food and Drug Administration to become the first provider of psychedelic-assisted therapy PTSD.
